Ardelyx Secures DDW IBS-C Poster Slot and Faces Potential Negative Earnings
Ardelyx’s abstract on IBS-C treatment patterns and gastrointestinal healthcare resource utilization was accepted for DDW 2026 poster presentation May 2-5 in Chicago, with a Product Theater session on May 5 led by Dr. Darren Brenner. Analysts project Ardelyx may report negative earnings next week due to insufficient profitability drivers.
1. IBS-C Poster Presentation Secured
An abstract exploring patient characteristics associated with IBS-C treatment changes and gastrointestinal healthcare resource utilization was accepted for poster Sa1729 at Digestive Disease Week 2026. The presentation is scheduled for May 2, 12:30–1:30 PM CT in Chicago.
2. Sponsored Product Theater Session
On May 5 at 3:00 PM CT, Ardelyx will host a Product Theater titled “IBS-C: Identifying and Managing the Symptoms,” led by Dr. Darren Brenner. The session will cover pathophysiology, case studies, and strategies to optimize care for adults with IBS-C.
3. Upcoming Earnings Projection
Analysts anticipate Ardelyx will report negative earnings next week, attributing the outlook to limited profitability drivers in its IBSRELA and XPHOZAH franchises and potential near-term revenue shortfalls.